Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC
  • CME
  • CE

In this module, 5 lung cancer experts review oncology healthcare professional survey results on key educational needs for the multidisciplinary oncology team caring for patients with EGFR-mutated NSCLC, including discussion of standard-of-care practices, the latest clinical data, and ongoing challenges.
Edward B. Garon, MD, MS
Program Director
Xiuning Le, MD, PhD
Zofia Piotrowska, MD, MHS
Mark A. Socinski, MD
Helena A. Yu, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.25 Nursing contact hours
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: September 30, 2022 Expiration: September 29, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC for evaluation of EGFR mutation status in newly diagnosed patients and those with acquired resistance following EGFR TKI therapy
  • Compare available efficacy and safety data of systemic therapies throughout the continuum of EGFR mutation–positive metastatic or locally advanced NSCLC from the first-line setting to the second-line setting and beyond (including outcomes by type of EGFR mutation and the presence of comutations)
  • Describe the biologic rationale for the design of clinical trials combining EGFR-targeted and VEGFR-targeted therapy in EGFR mutation–positive NSCLC and potential ramifications for practice based on recent clinical trial results
  • Plan therapy based on an understanding of the subtype of EGFR mutation as well as comutations such as TP53
  • Refine EGFR mutation–positive metastatic and locally advanced NSCLC treatment algorithms based on molecular profile and prior therapy expsoure in earlier lines of therapy
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for EGFR mutation–positive NSCLC


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Edward B. Garon, MD, MS

Thoracic Oncology Program
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics
Division of Hematology/Oncology
Department of Medicine
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Edward B. Garon, MD, MS: consultant/advisor/speaker: ABL Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Dracen, Eisai, EMD Serono, GlaxoSmithKline, Lilly, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio; researcher: ABL Bio, AstraZeneca, Bristol-Myers Squibb, Dynavax Technologies, EMD Serono, Genentech, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis.


Helena A. Yu, MD

Associate Attending
Department of Medicine
Section Head, Molecular Targets in Lung Cancer
Memorial Sloan Kettering Cancer Center
New York, New York

Helena A. Yu, MD: researcher (paid to her institution): AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Novartis, Pfizer; consultant/advisor/speaker: AstraZeneca, Blueprint Medicine, Daiichi Sankyo, Janssen Oncology.
Xiuning Le, MD, PhD

Assistant Professor
Division of Cancer Medicine
Department of Throracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Xiuning Le, MD, PhD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Lilly, Novartis, Spectrum; researcher: Boehringer Ingelheim, Regeneron.
Zofia Piotrowska, MD, MHS

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: researcher (paid to her institution): AbbVie, AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro; consultant/advisor/speaker: AstraZeneca, Blueprint, C4 Therapeutics, Cullinan Oncology, Genentech, Incyte, Janssen, Jazz, Lilly, Medtronic, Takeda.
Mark A. Socinski, MD

Executive Medical Director
Thoracic Oncology Program
AdventHealth Cancer Institute
Orlando, Florida

Mark A. Socinski, MD, consultant/advisor/speaker: AstraZeneca, BeiGene, G1 Therapeutics, Genentech, Guardant, Janssen, Jazz, Lilly, Regeneron, Takeda, Sanofi; researcher: AstraZeneca, BeiGene, Cullinan, Daiichi Sankyo, Genentech, Novartis, Spectrum, Takeda.


Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.
Jill Sakai, PhD

Editorial Contributor

Jill Sakai, PhD, has no relevant financial relationships to disclose.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.
Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC
Jacky Olin, PharmD, has no relevant financial relationships to disclose.
Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant financial relationships to disclose.
Kristen Rosenthal, PhD

Associate Director, Scientific Services

Kristen M. Rosenthal, PharmD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant financial relationships to disclose.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh has no relevant financial relationships to disclose.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with EGFR mutation–positive NSCLC.


The goal of this activity is to improve the knowledge, competence, and performance of learners to optimally integrate current data needed to make treatment decisions and improve outcomes in the EGFR mutation–positive NSCLC patient population.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-231-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 30, 2022, through September 29, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Released: January 23, 2023

On-demand webcast from a live satellite symposium at SITC 2022 on current use of IO therapy in lung cancer, from Clinical Care Options (CCO)

Julie R. Brahmer, MD
Program Director
person default Jarushka Naidoo, MB BCH BAO, MHS Zofia Piotrowska, MD, MHS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 17, 2023 Expired: January 16, 2024

Downloadable slides on multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer, from Clinical Care Options, (CCO)

Erika P. Hamilton, MD
Program Director
Joyce O'Shaughnessy, MD
Program Director
Released: January 4, 2023

Experts highlight key studies being presented at the 2022 ASH Annual Meeting in this commentary from Clinical Care Options (CCO)

Catherine M. Broome, MD John M. Burke, MD Corey Cutler, MD, MPH, FRCPC person default David Dingli, MD, PhD Amir T. Fathi, MD Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Marshall Mazepa, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Allison Wheeler, MD, MSCI Amer Zeidan, MBBS, MPH Released: December 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings